Cholinesterase inhibitors: beyond Alzheimer’s disease

References

• Lanctôt KL, Hermann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ169, 557–564 (2003).
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Ames D, Clayton T, Lai R. Meta-analysis of randomized trials of the efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer disease. Am. J. Geriatr. Psychiatry12, 358–369 (2004).
   PubMed Web of Science ®Google Scholar
• Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int. J. Geriatr. Psychiatry19, 624–633 (2004).
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. (1), CD005593 (2006).
   PubMedGoogle Scholar
• Takeda A, Loveman E, Clegg A et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int. J. Geriatr. Psychiatry21, 17–28 (2006).
   PubMed Web of Science ®Google Scholar
• Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev. (1), CD001190 (2006).
   Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev. (1), CD001747 (2006).
   Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst. Rev. (2), CD001191 (2006).
   Google Scholar
• Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, Dekosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer’s disease by cholinesterase inhibition. J. Am. Geriatr. Soc.53, 83–87 (2005).
   PubMed Web of Science ®Google Scholar
• Larner AJ. Do cholinesterase inhibitors alter the course of dementia? Prog. Neurol. Psychiatry11(5), 26–28 (2007).
   Google Scholar
• Inestrosa NC, Alvarez A, Perez CA et al. Acetylcholinesterase accelerates assembly of amyloid β-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron16, 881–891 (1996).
   PubMed Web of Science ®Google Scholar
• Larner AJ. Neuropsychological Neurology: the Neurocognitive Impairments of Neurological Disorders. Cambridge University Press, Cambridge, UK (2008).
   Google Scholar
• Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352, 2379–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst. Rev. (3), CD006104 (2006).
   Google Scholar
• Feldman HH, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol.6, 501–512 (2007).
   PubMed Web of Science ®Google Scholar
• Winblad B, Gauthier S, Scinto L et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology70, 2024–2035 (2008).
   PubMed Web of Science ®Google Scholar
• Mohan M, Carpenter PK, Bennett C. Donepezil for dementia in people with Down syndrome. Cochrane Database Syst. Rev. (1), CD007178 (2009).
   Google Scholar
• Mohan M, Carpenter PK, Bennett C. Rivastigmine for dementia in people with Down syndrome. Cochrane Database Syst. Rev. (1), CD007658 (2009).
   Google Scholar
• Mohan M, Carpenter PK, Bennett C. Galantamine for dementia in people with Down syndrome. Cochrane Database Syst. Rev. (1), CD007656 (2009).
   Google Scholar
• Winblad B, Black SE, Homma A et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr. Med. Res. Opin.25, 2577–2587 (2009).
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet356, 2031–2036 (2000).
   PubMed Web of Science ®Google Scholar
• Wesnes KA, McKeith IG, Ferrara R et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomized placebo-controlled international study using the cognitive drug research computerized assessment system. Dement. Geriatr. Cogn. Disord.13, 183–192 (2002).
   PubMed Web of Science ®Google Scholar
• Grace J, Daniel S, Stevens T et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int. Psychogeriatr.13, 199–205 (2001).
   PubMed Web of Science ®Google Scholar
• Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst. Rev. (3), CD003672 (2003).
   Google Scholar
• Edwards K, Royall D, Hershey L et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement. Geriatr. Cogn. Disord.23, 401–405 (2007).
   Google Scholar
• Aarsland D, Laake K, Larsen JP et al. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry72, 708–712 (2002).
   PubMed Web of Science ®Google Scholar
• Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int. J. Geriatr. Psychiatry19, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Leroi I, Collins D, Marsh L. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson’s disease: a review. J. Neurol. Sci.248, 104–114 (2006).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351, 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst. Rev. (1), CD004747 (2006).
   Google Scholar
• Almaraz AC, Driver-Dunckley ED, Woodruff BK et al. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist15, 234–237 (2009).
   PubMedGoogle Scholar
• Dubois B, Tolosa E, Kulisevsky J et al. Efficacy and safety of donepezil in the treatment of Parkinson’s disease patients with dementia. Neurodegen. Dis.4(Suppl. 1), 90 (2007).
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Parkinson’s Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Royal College of Physicians, London, UK (2006).
   Google Scholar
• Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology57, 467–473 (2001).
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke35, 1010–1017 (2004).
   PubMed Web of Science ®Google Scholar
• Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev. (1), CD004395 (2004).
   Google Scholar
• Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale trials. Dement. Geriatr. Cogn. Disord.20, 338–344 (2005).
   PubMed Web of Science ®Google Scholar
• Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst. Rev. (2), CD004744 (2005).
   Google Scholar
• Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst. Rev. (1), CD004746 (2006).
   Google Scholar
• Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol.6, 782–792 (2007).
   PubMed Web of Science ®Google Scholar
• Kwon JC, Kim EG, Kim JW et al. A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia. Am. J. Alzheimers Dis. Other Demen.24, 293–301 (2009).
   PubMedGoogle Scholar
• Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state. Observations in CADASIL. Neurology60, 1183–1185 (2003).
   PubMed Web of Science ®Google Scholar
• Dichgans M, Markus HS, Salloway S et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol.7, 310–318 (2008).
   PubMed Web of Science ®Google Scholar
• Wright RA, Boeve BF, Malec JF. Amnesia after basal forebrain damage due to anterior communicating artery aneurysm rupture. J. Clin. Neurosci.6, 511–515 (1999).
   PubMedGoogle Scholar
• Lyketsos CG. Brain tumors, systemic lupus erythematosus, HIV/AIDS, and Wilson’s disease. In: Psychiatric Aspects of Neurologic Diseases. Practical Approaches to Patient Care. Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR (Eds). Oxford University Press, NY, USA, 305–320 (2008).
   Google Scholar
• Davies M, Larner AJ. Clinical misdiagnosis of Alzheimer’s disease: getting it wrong again. Eur. J. Neurol.16(Suppl. 3), 351 (abstract 2036) (2009).
   Google Scholar
• Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging21, 931–937 (2004).
   PubMed Web of Science ®Google Scholar
• Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioural worsening on donepezil in patients with frontotemporal dementia. Am. J. Geriatr. Psychiatry15, 84–87 (2007).
   PubMed Web of Science ®Google Scholar
• Kertesz A, Morlog D, Light M et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement. Geriatr. Cogn. Disord.25, 178–185 (2008).
   PubMed Web of Science ®Google Scholar
• Kertesz A. Clinical features and diagnosis of frontotemporal dementia. In: Dementia in Clinical Practice. Giannakopoulos P, Hof PR (Eds). Karger, Basel, Switzerland, 140–148 (2009).
   Google Scholar
• Cubo E, Shannon KM, Tracy D et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology67, 1268–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenblatt A. Huntington’s disease. In: Psychiatric Aspects of Neurologic Diseases. Practical Approaches to Patient Care. Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR (Eds). Oxford University Press, NY, USA, 251–265 (2008).
   Google Scholar
• Greene YM, Tariot PN, Wishart H et al. A 12-week open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J. Clin. Psychopharmacol.20, 350–356 (2000).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology63, 1579–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Parry AMM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain126, 2750–2760 (2003).
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can. J. Neurol. Sci.35, 476–481 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher RS, Bortz JJ, Blum DE, Duncan B, Burke H. A pilot study of donepezil for memory problems in epilepsy. Epilepsy Behav.2, 330–334 (2001).
   PubMed Web of Science ®Google Scholar
• Hamberger MJ, Palmese CA, Scarmeas N, Weintraub D, Choi H, Hirsch LJ. A randomized double-blind placebo-controlled trial of donepezil to improve memory in epilepsy. Epilepsia48, 1283–1291 (2007).
   PubMed Web of Science ®Google Scholar
• Griffith HR, Martin R, Andrews S et al. The safety and tolerability of galantamine in patients with epilepsy and memory difficulties. Epilepsy Behav.13, 376–380 (2008).
   PubMedGoogle Scholar
• Overshott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane Database Syst. Rev. (1), CD005317 (2008).
   Google Scholar
• Liptzin B, Laki A, Garb JL, Fingeroth R, Krushell R. Donepezil in the prevention and treatment of post-surgical delirium. Am. J. Geriatr. Psychiatry13, 1100–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Sampson EL, Raven PR, Ndhlovu PN et al. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int. J. Geriatr. Psychiatry22, 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Ballesteros J, Guemes I, Ibarra N, Quemada JI. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J. Head Trauma Rehabil.23, 171–180 (2008).
   PubMed Web of Science ®Google Scholar
• Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufik S. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest133, 677–683 (2008).
   PubMed Web of Science ®Google Scholar
• Moraes W, Sukys-Claudino L, Poyares D, Tufik S. Donepezil treatment for sleep apnoea in non-demented patients. Eur. J. Neurol.16(Suppl. 3), 620 (abstract 2827) (2009).
   Google Scholar
• Staszewski J, Stepien A. Efficacy of rivastigmine treatment in narcolepsy: report of 2 cases. Eur. J. Neurol.16(Suppl. 3), 624 (abstract 2841) (2009).
   PubMedGoogle Scholar
• Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs24, 303–317 (2010).
   PubMed Web of Science ®Google Scholar
• Iosifescu DV, Moore CM, Deckersbach T et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS Neurosci. Ther.15, 309–319 (2009).
   PubMedGoogle Scholar
• Shaw EG, Rosdhal R, D’Agostino RB Jr et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J. Clin. Oncol.24, 1415–1420 (2006).
   PubMed Web of Science ®Google Scholar
• Noyan MA, Elbi H, Aksu H. Donepezil for anticholinergic drug intoxication: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry27, 885–887 (2003).
   PubMed Web of Science ®Google Scholar
• Alisky JM. Could cholinesterase inhibitors and memantine alleviate HIV dementia? J. Acquir. Immune Defic. Syndr.38, 113–114 (2005).
   PubMed Web of Science ®Google Scholar
• Gill SS, Anderson GM, Fischer HD et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch. Intern. Med.169, 867–873 (2009).
   PubMedGoogle Scholar
• Larner AJ. Transdermal rivastigmine for Alzheimer’s disease: skin deep or scratching the surface? Int. J. Clin. Pract.64, 534–536 (2010).
   PubMedGoogle Scholar